PF-07832837 is under clinical development by Pfizer and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback